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Abstract
The ability to induce antibody responses to pathogens while maintaining the quiescence of
autoreactive cells is an important aspect of immune tolerance. During activation of Toll-like
receptor-4 (TLR4), dendritic cells (DCs) and macrophages (MFs) repress autoantibody production
through their secretion of IL-6 and soluble CD40L (sCD40L). These soluble mediators selectively
repress B cells chronically exposed to antigen, but not naïve cells, suggesting a means to maintain
tolerance during TLR4 stimulation, yet allow immunity. In this study, we identify TNFα as a third
repressive factor, which together with IL-6 and CD40L, account for nearly all the repression
conferred by DCs and MFs. Like IL-6 and sCD40L, TNFα did not alter B cell proliferation or
survival. Rather, it reduced the number of antibody secreting cells. To address whether the soluble
mediators secreted by DCs and MFs functioned in vivo, we generated mice lacking IL-6, CD40L
and TNFα. Compared to wildtype mice, these mice showed prolonged anti-nuclear antibody
responses following TLR4 stimulation. Further, adoptive transfer of autoreactive B cells into
chimeric IL-6-/- × CD40L-/- × TNFα-/- mice showed that pre-plasma cells secreted autoantibodies
independent of germinal center formation or extrafollicular foci. These data indicate that in the
absence of genetic predisposition to autoimmunity, loss of endogenous IL-6, CD40L, and TNFα
promotes autoantibody secretion during TLR4 stimulation.
Introduction
Toll-like receptor-4 (TLR4) is a germline encoded innate immune receptor that recognizes
lipopolysaccharide (LPS) and promotes the secretion of inflammatory mediators and
antibodies (1). TLR4 plays a role in the immune response to tissue injury (7, 8, 12-16) and
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multiple self-proteins released from necrotic cells or damaged tissues have been found to
activate and/or bind TLR4 (reviewed in 2, 3). These include heat shock protein gp96 (4),
HMGB1 (reviewed 5, 6), dysfunctional mitochondria (7), and endogenous lipoproteins
(8-11). The findings that host-derived endogenous ligands, or DAMPs, bind TLR4 suggests
the possibility that autoimmunity could arise from an inability to regulate TLR4-expressing
autoreactive B cells or myeloid cells. In support of this, gene deletion and overexpression
studies identify TLR2, TLR4, and TLR7 as contributing to autoantibody titers, renal disease,
and the heightened cytokine production found in lupus-like autoimmune disease in mice (4,
17). TLR4 is also required for autoimmunity and organ injury in experimental lupus induced
by pristine (18). Further, repeat injections of low-dose LPS into lupus-prone mice accelerate
the development of disease, increases autoantibody levels, and worsens renal impairment
(19-21). This indicates that innate immune responses involving TLR4 contribute to
pathogenic autoantibody production in lupus-prone mice.
B lymphocytes express most TLRs and respond to their ligands by proliferating, expressing
co-stimulatory molecules, and secreting immunoglobulin (Ig). We identified that
autoreactive B cells are regulated during TLR4 activation by myeloid dendritic cells (DCs)
and macrophages (MF) (22, 23). Regulation of autoantibody secretion is conferred in part by
IL-6 and soluble CD40L (sCD40L) secreted from TLR4-activated MFs and myeloid DCs. A
unique feature of DC/MF-mediated tolerance is that B cells chronically exposed to self-
antigen are affected by IL-6 and sCD40L, while antigenically naïve B cells are unaffected.
The data show that chronic B cell antigen receptor (BCR) signaling, as a consequence of
self-antigen exposure, integrates with acute IL-6 receptor or CD40 signals to repress TLR4-
induced Ig secretion in B autoreactive, but not in antigenically naïve B cells (23). DC/MF
defects are apparent in lupus-prone MRL/lpr mice where reduced secretion of IL-6 and
sCD40L occurs coincident with a diminished ability to repress TLR4-induced Ig secretion
(22, 23). Collectively the data indicate that DCs and MFs are key regulatory cells that
maintain B cell tolerance during TLR4-induced innate immune responses, and that defects in
this tolerance mechanism might contribute to the early autoantibody production associated
with disease.
In this study, we describe TNFα as a third factor produced by LPS-activated DCs and MFs
that represses autoantibody production, and we assess whether DCs and MFs regulate
autoreactive B cells in vivo. We find that compared to DCs and MFs from C57BL/6 (B6)
mice, those from lupus-prone MRL/lpr mice produce less TNFα suggesting that diminished
TNFα may contribute to a break in tolerance. In vivo we show that IL-6, CD40L, and TNFα
regulate B cell tolerance during innate immune responses as mice deficient for these three
factors (IL-6-/- × CD40L-/- × TNFα-/-; 3XKO) exhibited prolonged anti-nuclear and anti-
nucleosome antibody responses. Adoptive transfer studies show that Sm-specific pre-plasma
cells that were adoptively transferred into bone marrow chimeras lacking IL-6, CD40L, and
TNFα secreted anti-Sm during an ongoing TLR4 response. The findings that loss of IL-6,
sCD40L and TNFα leads to a breach in tolerance in the absence of genetic predisposition
establishes that the regulation of autoreactive B cells in vivo relies on DCs and MFs during
TLR4-induced innate immune responses.
Materials and Methods
Mice
Ars/A1, 125Tg, 2-12H, and 2-12H/Vκ8 mice have been previously described (24-28).
C57BL/6J, MRL/MpJ-Faslpr/J (MRL/lpr), IL-6-/-, CD40L-/- and TNFα-/- mice were
purchased from the Jackson Laboratory. IL-6-/-, CD40L-/- and TNFα-/- mice were crossed to
generate the IL-6-/- × CD40L-/- × TNFα-/- (3XKO) mice. B6.SJL-Ly5.2/Cr mice (C57BL/6
mice expressing the Ly5.1 antigen from SJL/J mice) were purchased from the National
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Cancer Institute. The Institutional Animal Care and Use Committee at the University of
North Carolina approved all animal experiments.
Bone Marrow Transplant
Six- to eight-week-old B6.SJL-Ly5.2/Cr mice were lethally irradiated (900 rads). Twenty-
four hours later 5-8×106 bone marrow cells from C57BL/6 or 3XKO donor mice were
transferred. These chimeras are referred to as B6 chimeras and 3XKO chimeras,
respectively. After 8 weeks, the expression of Ly5.1 or Ly5.2 was assessed as a means to
distinguish donor and recipient cells following reconstitution.
Bone marrow-derived DC (BMDC) and MF (BMMF) Cultures
BMDCs (95% pure) and BMMFs (98% pure) were generated as previously described (22).
Conditioned medium (CM) was made from 1×104 BMDCs and BMMFs (0.2 ml) cultured 4
days with or without Sigma LPS (30 μg/ml) or InvivoGen LPS (10 ng/ml).
Reagents and Antibodies
LPS was purchased from Sigma Aldrich (Escherichia coli 055:B5) and Invitrogen
(Escherichia coli 0111:B4). R848 was purchased from Enzo Life Sciences, CpG-B (1826)
and non-CpG (2138) oligodeoxynucleotides (ODN) from Coley Pharmaceutical Groups.
Recombinant IL-6 and antibodies to IL-6, CD40L, B220, Thy1.2, CD11b, CD11c, CD21,
CD23, CD138, CD19 CD90.2, streptavidin PE-Cy5.5 and hamster IgG3 were purchased
from BD Biosciences. TEPC 183, and rabbit IgG were purchased from Sigma-Aldrich,
mouse GM-CSF, IL-4, and M-CSF from PeproTech, CFSE, and streptavidin Alexa 488
from Invitrogen, and recombinant TNFα and recombinant soluble CD40L from R&D
Systems. Monoclonal antibodies 54.1 (3-83 idiotype), 187.1 (anti-κ), HB100 (anti-IgMa),
B7.6 (anti-IgM), RS3.1 (IgMa), and PL2-6 (anti-nucleosome) were purified from hybridoma
culture supernatants. Rabbit polyclonal anti-TNFα was obtained from Vic Johnson (CDC/
NIOSH/HELD, West Virginia) and affinity purified using Protein A.
B Cell Purification and Cell Sorting
Splenic B cells were negatively selected using the StemSep B cell enrichment kit (StemCell
Technologies). B cell purity ranged from 85-97%. B cell populations from 2-12H mice (92%
IgMa (27) were sorted on a MoFlo high-speed sorter (DakoCytomation) as previously
described (29). Briefly, CD19+ cells were gated for CD21, CD23, and CD138. Cells were
divided into populations by staining patterns: follicular (FO; CD19hi CD21med, CD23hi,
CD138lo), marginal zone (MZ; CD19hi CD21hi, CD23lo/med, CD138lo) and pre-plasma cells
(prePC; CD19hi, CD138med). Populations were >90% pure on re-analysis.
B Cell Culture
Purified B cells (1×105 per well in a 96-well plate) were cultured with 30 μg/ml LPS for 4
days. Recombinant IL-6, rsCD40L, rTNFα, CHO-TNFα, BMDC or BMMF conditioned
media (CM) (25% of final volume) were added to B cell cultures on day 0. The IL-6 in CM
was neutralized with either anti-IL-6 antibody or a control rat IgG1 antibody (54.1). Soluble
CD40L in CM was neutralized with either anti-CD40L or control hamster IgG3 antibody.
TNFα in CM was neutralized with either anti-TNFα or control rabbit IgG.
ELISA
IgMa/κ (encoded by 2-12H/Vk8, Ars/A1 and 125Tg) was captured with anti-κ (clone
187.1). Total IgM (B6 mice) was captured with anti-IgM (clone 33-60), nucleosome-specific
Ig with histones (4 μg/well; Immunovision) and dsDNA (1 μg/well; Sigma), and TNFα
with anti-TNFα (clone TN3-19, eBioscience). Captured antibodies were detected with
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biotinylated anti-IgMa (clone HB100), anti-IgM (clone B7.6), anti-mouse Ig (IgG, IgM, and
IgA), or polyclonal anti-TNFα (eBioscience), respectively. TEPC 183 (IgMa/κ), PL2-6
(anti-nucleosome) and rTNFα served as standards. All assays were visualized using
streptavidin-alkaline phosphate (Southern Biotech) and 4-nitrophenyl phosphate disodium
salt hexahydrate (Sigma). Data were plotted as percent of control calculated relative to
cultures of LPS-stimulated B cells.
Antinuclear Antibody (ANA) Assay
Hep-2 substrate slides (Antibodies Inc.) were used to detect serum (1:50 dilution)
autoantibodies. Nuclear and cytoplasmic staining was identified using anti-mouse IgG-
Alexa 488 or IgM-Alexa 647 (Invitrogen). Based on the guidelines for fluorescent antibody
reagents established by the Center for Disease Control, the fluorescence of the IgM and IgG
staining was quantitated using a scale of 0–4, and the values from multiple mice compiled.
Immunohistochemistry
Chimeric mice were pretreated with LPS (25 μg) on days -10 and -3. On day 0, 15 × 106
negatively selected B cells (2-12H) were tail vein injected. On days 4 and 7, spleens were
flash frozen in Optimal Cutting Temperature Compound (OCT; TissueTek), sectioned to
8μm, and fixed in acetone/methanol (1:2) for 5 minutes. Rehydrated sections were blocked
for 1 hour in Superblock (Pierce) diluted 1:2 in PBS containing 10 μg/ml 2.4G2 (anti-
FcγRII/III), stained for 1 hour, and mounted with DAPI Prolong Gold (Invitrogen) or
FluroSave (Calbiochem). Images were viewed using digital deconvolution microscopy and
processed using Slidebook software (Intelligent Imaging Innovations). The numbers of
IgMa+ and CD138+ cells in each field were quantified. These cells were present throughout
the red pulp and areas of the follicles. The percent of transferred cells that became ASCs
was determined by calculating the percent of IgMa+ cells that were also CD138+. To assess
splenic architecture (Figure 5A) of 3XKO, 3XKO chimera, and B6 mice, we counted at least
8 (and as many as 44) follicles from each group and enumerated the follicles that contained
distinct PALs. The data are expressed as percent of total follicles counted.
In vivo stimulation
To induce an innate immune response, an injection of 1.25 mg/kg, 0.9 mg/kg, or 0.625 mg/
kg (25μg, 18 μg, 12.5 μg/injection/mouse) of LPS were injected i.p. on days 0, 7, and 14
(Figure 4), or on days -10 and -3 (Figure 5).
ELISPOT
Following adoptive transfer, 5×106 splenocytes were plated onto anti-kappa (187.1) or anti-
IgMa (RS3.1) coated plates. Bound antibody was detected using biotin-labeled anti-IgM
(B7.6) and streptavidin-HRP (BD Biosciences), and visualized using 3-amino-9-
ethylcarbazole (Sigma-Aldrich) at 24 hours. Spots were enumerated using the Immunospot
Analyzer and Cellular Technologies software. To assess the effect of TNFα on ASC
formation, 4 × 103 cultured B cells were serially diluted and cultured on anti-kappa coated
ELISPOT plates. Eight hours later, plates were washed and bound antibody was visualized
as above.
CFSE-based Proliferation Assay
B cell proliferation was assessed by the dilution of 5-carboxyfluorescein diacetate
succinimidyl ester (CFSE) loaded cells as previously described (23).
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Antibody or cytokine secretion between treated and untreated cultures was analyzed using a
one-sampled t test. Comparison of antibody production between experimental groups was
analyzed using the Wilcoxon rank-sum test. Statistical analysis was preformed with
GraphPad Prism (v4.0c, 2005).
Results
DCs and MFs regulate Ig secretion from TLR4-activated autoreactive B cells
Self-antigens and pathogen-associated antigens bind TLR4 thus requiring that tolerance
mechanisms regulate autoreactive B cells to protect from autoimmunity (6, 30). As shown in
Figure 1A, and previously reported (22, 23), LPS stimulated Sm-specific B cells from
2-12H/Vκ8 mice are repressed by IL-6 and sCD40L, the secreted products of LPS-activated
dendritic cells (DCs) and macrophages (MFs). In this model, conditioned medium (CM)
from bone marrow-derived DCs (BMDCs) and MFs (BMMFs), recombinant IL-6 (rIL-6)
and recombinant soluble CD40L (rsCD40L) repressed 50% to 75% of Ig secretion (Figure
1A). Similarly, the secreted products from DCs and MFs repressed 40 to 60% of Ig secretion
from 2-12H B cells (Figure 1B), but not from B6 B cells, which are predominately
antigenically naive (Figure 1C). These findings show that during TLR4 activation, DCs and
MFs secrete soluble factors that repress TLR4-induced Ig secretion from B cells chronically
exposed to self-antigen, but not antigenically naive cells. In this in vitro culture model, one
possible caveat was that the dose of LPS used for maximal B cell Ig secretion (30 μg/ml)
was in excess of that required to activate DCs and MFs (6, 31, 32) and could induce non-
physiological levels of IL-6 and sCD40L. To address whether the repressive effect was the
result of the dose of LPS, or a unique property of the LPS, we used a second source of LPS
and a lower dose (10 ng/ml). This dose induces cytokine secretion by MFs and approximates
the endotoxin concentration when cells are treated with live E. coli (one bacterium per MF;
(31). We found that MF CM prepared using InvivoGen LPS (10 ng/ml) was as efficient at
repressing Ig secretion as the 30 μg/ml dose of Sigma LPS; neither dose repressed TLR4-
induced Ig from B6 B cells (Figure 1D). This indicates that repression of LPS-induced Ig
secretion by DCs and MFs is not dependent on the source or dose of the LPS.
The mechanisms that maintain autoreactive B cells in an unresponsive state during TLR
activation have not been well studied. In ssDNA-specific B cells, activation of TLR9 is
regulated by the exclusion of TLR and BCR-containing vesicles from the late endosome
(33). In HEL-specific B cells, chronic binding of high affinity antigen is sufficient to repress
TLR4 and TLR9 (34, 35). Mechanisms that regulate autoantibody secretion through TLR7
have not been described. Although TLR7 and TLR9 are localized within late endosomes
while TLR4 is surface expressed, they are similar in that they are coupled to MyD88. To
address whether IL-6 and sCD40L repressed autoreactive B cells stimulated through TLR7
and TLR9, we prepared CM from MFs and DCs stimulated with R848, CpG ODN, or
control CpG, then assessed whether the day 4 CM repressed TLR7- or TLR9-stimulated B
cells. Supernatants from R848 stimulated MFs or DCs failed to repress R848 stimulated
2-12H B cells (Figure 1E). Similarly, CpG stimulation of MFs or DCs failed to induce a
soluble factor that repressed CpG-treated 2-12H B cells (Figure 1F). This indicates that Ig
secretion from autoreactive Sm-specific B cells stimulated through TLR7 and TLR9 is not
regulated by the same mechanism as TLR4.
DCs and MFs repress autoantibody secretion through TNFα
Regulation of TLR4-induced Ig secretion occurs by the secretion of IL-6 from LPS-
activated DCs, and IL-6 and sCD40L from MFs. To address whether IL-6 and sCD40L were
the only repressive factors involved, we assessed the ability of DC CM from IL-6 deficient
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mice to repress LPS-induced Ig secretion, since the predominant repressive factor secreted
by DCs is IL-6. However, we found that CM from IL-6-deficient DCs still repressed 45% of
Ig secretion, compared to 60% repression by B6 DC CM (Figure 2A). This suggests that
DCs secrete another factor(s) that represses autoantibody production during innate immune
responses.
To identify other factor(s) that regulated autoantibody secretion, we neutralized DC CM
from IL-6-/- mice (IL-6-/- DC CM) with a panel of antibodies to cytokines and chemokines.
We found that neutralizing antibodies to TNFα restored Ig secretion from LPS-stimulated
2-12H/Vκ8 B cells to 78% of control, while addition of an unrelated antibody did not have a
significant effect (Figure 2A). This suggests that in addition to IL-6, DCs secrete TNFα to
regulate TLR4-induced Ig secretion.
To corroborate the finding that TNFα regulates autoreactive B cells, we assessed whether
recombinant TNFα (rTNFα) repressed LPS-induced Ig secretion. We found that 50 ng/ml of
rTNFα repressed 30% of Ig secretion by 2-12H/Vκ8 B cells (Figure 2B). Although rTNFα
was repressive, it was considerably less effective compared to rIL-6 or rsCD40L (Figure 2B;
(22, 23). To ensure that the low level of repression was not due to limited bioactivity of the
rTNFα, we expressed murine TNFα trimers in CHO cells. Addition of increasing amounts
of highly bioactive TNFα to the B cell cultures did not further diminish the level of Ig
secretion (data not shown). These data indicate that during LPS stimulation, TNFα modestly
regulates Ig secretion by autoreactive B cells.
To determine whether IL-6, sCD40L and TNFα were the only repressive factors that
regulated autoreactive B cells, we neutralized CM from B6 DCs (Figure 2C) and MFs
(Figure 2D) with antibodies to IL-6, CD40L and TNFα. Neutralization of IL-6 or TNFα
from DC CM had a partial effect while neutralizing both factors restored Ig secretion to
levels that were not significantly different from LPS-stimulated B cells (74%; Figure 2C).
Similarly, neutralizing MF CM with antibodies to IL-6, CD40L, or TNFα partially restored
Ig secretion while neutralizing with antibodies to all three factors restored Ig secretion to
81% of control, a level not statistically different from LPS-stimulated B cells (Figure 2D).
Collectively, the data show that TNFα represses autoantibody secretion; however TNFα is
not as potent as IL-6 and sCD40L in regulating Ig secretion.
TNFα represses autoreactive B cells, but not antigenically naïve cells
Our previous data showed that IL-6 and sCD40L repressed B cells that were chronically
exposed to self-antigen including Sm-, Ars- and HEL-specific B cells (HEL-Ig × sHEL).
However, it did not significantly diminish the amount of Ig secreted by B cells from B6 or
HEL-Ig mice (22, 23). We compared the ability of rTNFα to selectively repress LPS-
induced Ig secretion from B6 B cells compared to several transgenic lines specific for self-
antigens. B cells from Ars/A1 immunoglobulin transgenic mice bind Ars and ssDNA and
are repressed by IL-6 and sCD40L (22-24). TNFα repressed 26% of Ig secretion by Ars-
specific B cells, 17% of insulin-specific (125Tg) Ig secretion, and 30% of Sm-specific
(2-12H/Vκ8) Ig secretion (Figure 3A right panel). However, TNFα did not repress Ig
secretion by antigenically naïve B cells from B6 mice (Figure 3A left panel). These data
show that TNFα modestly represses Ig secretion from B cells of multiple autoreactive
specificities suggesting that chronic exposure to self-antigen integrated with co-ligation of
TNF receptor(s) stimulation attenuates TLR-induced Ig secretion.
TNFα represses Ig secretion by diminishing the number of antibody secreting cells
We previously found that sCD40L and IL-6 did not affect the proliferation of autoreactive B
cells; rather, they regulated autoantibody production by diminishing the number of B cells
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that became antibody secreting cells (ASCs; (23). To define whether TNFα functioned by a
similar mechanism, we used ELISPOT to compare ASC formation in the presence or
absence of TNFα. We found that TNFα treatment of LPS-stimulated B cells (2-12H/Vκ8)
diminished the number of ASCs by 25% (Figure 3B). This modest decrease is consistent
with the effect of rTNFα on Ig secretion (Figure 2B and 3A right panel).
TNFα might also diminish the rate of B cell proliferation as a means of affecting Ig
secretion. To assess this, we compared the rate of proliferation of B cells from 2-12H/Vκ8
mice that were untreated or treated with TNFα. The dilution of CFSE was similar between
untreated B cells from B6 and 2-12H/Vκ8 mice (proliferative index (PI)= 7.6 vs 5.5).
Addition of rTNFα to B cells from 2-12H/Vκ8 mice did not alter the rate of proliferation, as
the profiles of CSFE dilution were indistinguishable (Figure 3C; PI = 5.5 -TNFα; 5.6
+TNFα). This indicates that the ability of TNFα to diminish Ig secretion does not reflect
diminished proliferation of autoreactive cells.
DCs and MFs from lupus-prone mice are defective in secreting TNFα
Defects in the ability of DCs and/or MFs to secrete repressive factors might underlie the
break in tolerance associated with autoimmunity. Our studies of IL-6 and sCD40L showed
that DCs and MFs from lupus-prone mice are defective in repressing Ig secretion, coincident
with the reduced secretion of these repressive factors (22, 23, 36). To determine whether
DCs and MFs from lupus-prone mice were defective in secreting TNFα, we quantitated
TNFα by ELISA. LPS-stimulated BMDCs from lupus-prone MRL/lpr mice secreted
significantly less TNFα than LPS-stimulated B6 BMDCs (Figure 3D left). Macrophages
from MRL/lpr mice also secreted less TNFα compared to B6 (Figure 3D right). Taken
together, the data show that DCs and MFs from MRL/lpr mice are defective in secreting
IL-6, sCD40L and TNFα, soluble mediators that regulate autoreactive B cells during TLR4
stimulation (23, 36).
In the absence of IL-6, CD40L and TNFα, LPS stimulation induces ASC formation
In non-autoimmune mice, innate stimulation induces autoantibody production, however
these responses begin to resolve within four weeks (19-21). To define whether IL-6,
sCD40L and TNFα were important in maintaining B cell tolerance in vivo, we generated
mice deficient in the repressive factors (IL-6-/- × CD40L-/- × TNFα-/-; 3XKO). 3XKO mice
aged for one year in a pathogen free environment did not spontaneously develop
autoimmunity as evidenced by the lack of inflammation/mononuclear cell inflammation in
the kidneys, and the absence of serum anti-nucleosome antibody (data not shown). To assess
the role of the repressive factors during TLR4 stimulation in vivo, we LPS (1.25 mg/kg)
injected 3XKO and B6 mice and compared the course of autoantibody production. After
three intraperitoneal injections (days 0, 7, and 14), we monitored the formation of serum
autoantibodies by Hep-2 staining and anti-nucleosome antibody by ELISA. We
hypothesized that if IL-6, sCD40L, and TNFα were necessary to repress autoreactive B cells
in vivo, then the duration of the LPS-induced autoantibody response would be prolonged,
although both strains of mice were expected to eventually resolve the LPS challenge since
neither was genetically predisposed to disease. Three days after the last LPS injection (day
17), we found that the IgM and IgG staining of Hep-2 cells from both B6 and 3XKO mice
was apparent indicating that the absence of the IL-6, CD40L and TNFα did not ablate
autoantibody secretion (Figure 4A row 2 compared to 4). In B6 mice, the robust IgM
response waned over time while the response in 3XKO was prolonged (Figure 4A row 2
compared to 4; IgM stain; scoring in Figure 4B). The IgG response became evident in both
B6 and 3XKO on day 17 (Figure 4C). In 3XKO mice the IgG response was sustained over
time and exhibited a nuclear staining pattern around day 28 (Figure 4A row 2 compared to
4; IgG stain). In B6 mice, the response was diminished by day 28 and a nuclear staining
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pattern was never evident. Continued monitoring of 3XKO mice showed that the IgG
response remained high at day 42, but was attenuated by day 60 (data not shown). In the
absence of LPS, the 3XKO mice did not show elevated serum antinuclear antibody levels
(Figure 4A rows 1 and 3). Mice lacking IL-6, CD40L, and TNFα also exhibited a prolonged
serum anti-nucleosome response (Figure 4D). B6 and 3XKO mice also mounted comparable
anti-nucleosome responses at day 17 (3 days after LPS priming). However, at day 21 (1
week after LPS priming), the B6 mice reduced the anti-nucleosome response by >50% while
the antibody levels in the 3XKO mice remained unchanged. Consistent with the presence of
IgM and IgG in the Hep2 staining, we found that the anti-nucleosome antibody response
contained both IgM and IgG, although IgM predominated (data not shown). This suggests
that the nuclear IgG response in the Hep-2 staining might be due to the low levels of anti-
nucleosome IgG, while the IgM staining (day 17), is a specificity other than anti-
nucleosome, such as anti-mitochondrial or anti-smooth muscle antibody, which stain the
cytoplasm. The diminished ability of 3XKO mice to resolve the autoantibody response
remained evident for three weeks. At week five (day 35) the anti-nucleosome response in
3XKO mice was reduced to levels similar to those in B6 mice. The eventual restoration of
tolerance is consistent with the fact that the 3XKO mice lack genetic modifiers that
predispose to autoimmune disease. To ensure this was not due to the dose of LPS, we
injected two other cohorts of mice with lower doses of LPS (0.9 mg/kg and 0.625 mg/kg).
We found that 0.9 mg/kg of LPS induced a robust anti-nucleosome antibody response in the
3XKO mice that failed to resolve until day 35 (Figure 4E); however, this dose was
suboptimal for the B6 mice. This suggests that the threshold for LPS-induced Ig secretion is
lower in the absence of the repressive cytokines. The low dose of LPS (0.625 mg/kg) failed
to induce an anti-nucleosome antibody response above the prebleed in the B6 mice (data not
shown). Taken together, the data indicate that loss of IL-6, CD40L and TNFα does not
result in spontaneous autoimmunity, however it leads to prolonged autoantibody production
in response to LPS. This is consistent with an in vivo role for IL-6, sCD40L, and/or TNFα
in resolving autoantibody secretion following TLR4 stimulation.
Sm-specific B cells become activated when transferred into chimeric 3XKO mice
Previous studies showed that mice lacking CD40L and TNFα have immune defects
including the inability to form germinal centers, abnormal class switch recombination, and
poorly defined splenic B and T cell regions (37-40). These deficiencies could alter the
course of antibody production in the 3XKO mice due to splenic abnormalities not related to
tolerance. To address this issue, we generated chimeras by transplanting bone marrow from
B6 or 3XKO mice (Ly5.1) into lethally irradiated B6.SJL-Ly5.2/Cr mice to generate B6 and
3XKO chimeras. As shown in Figure 5A, the organization of the splenic B cell follicles and
T cell regions of the 3XKO chimera was comparable to the chimeric B6 mice and B6
control mice while the non-chimeric 3XKO mice mostly showed poorly defined B and T
regions. We found that about 25% of the architecture within the nonchimeric 3XKO spleen
showed organized B and T regions, while the red pulp did not display any apparent
abnormalities (see M&M for quantitation method). This might provide an explanation for
the IgG ANA response in 3XKO mice despite lacking TNFα (Figure 4A row 4).
To determine whether autoreactive B cells from mice lacking the repressive factors would
break tolerance during TLR4 stimulation, we transferred Sm-specific B cells (2-12H) into
chimeric B6 and 3XKO mice. Chimeric mice were given two LPS injections (1.25 mg/kg)
seven days apart, followed by intravenous injection of purified B cells from 2-12H/B6 mice
(IgMa allotype) (Figure 5B). Three days post-transfer we enumerated Sm-specific (anti-
IgMa) ASC (Figure 5C) by ELISPOT. The data show that transferred 2-12H B cells were
modestly activated in the LPS-primed B6 mice compared to mice that did not have cells
transferred indicating that sufficient LPS remained in the system for B cell activation
Gilbert et al. Page 8













(Figure 5C). Compared to B6 chimeras where IL-6, CD40L and TNFα remain intact, the
transfer of 2-12H B cells into 3XKO chimeric mice showed a 2.5-fold increase in the
formation of ASCs by day 3 post-transfer (Figure 5C left panel). Twelve days after B cell
transfer into 3XKO, donor IgMa+ ASCs were no longer evident (Figure 5C right panel).
Similar results were found using anti-Sm ELISPOTS. Additionally, there were no anti-Sm
(or IgMa+) ASCs present in the bone marrow of the chimeric mice at any time points (data
not shown), indicating that plasma cells had not migrated to the bone marrow. Mice that
were not injected with LPS did not show any antibody responses indicating that the response
seen in treated mice was the result of LPS-mediated B cell activation. These data indicate
that the absence of IL-6, sCD40L, and TNFα in hematopoietic cells, allows autoreactive B
cells to secrete Ig during a TLR4 response demonstrating that these factors play a role in B
cell tolerance in vivo.
In the absence of IL-6, CD40L and TNFα, pre-plasma cells become activated
The marginal zone (MZ) and pre-plasma cell (prePC) subsets have been described as early
responders during innate responses (41-43). To define the splenic B cell subsets responsible
for the day 3 response, we adoptively transferred sorted follicular (FO; CD19hi CD21med,
CD23hi, CD138lo), marginal zone (MZ; CD19hi CD21hi, CD23lo/med, CD138lo) and pre-
plasma cells (prePC; CD19hi, CD138med) from 2-12H mice into LPS-primed B6 and 3XKO
chimeric mice. Three days post-transfer, the numbers of IgMa-specific ASCs were
enumerated by ELISPOT. As shown in Figure 5D, the numbers of ASCs that formed from
transferred MZ and FO were equal between B6 and 3XKO chimeras. However, the numbers
of transferred pre-PCs that became ASCs in the 3XKO chimeras was increased
approximately 2-fold compared to transfer into B6 chimeras. This indicates that the pre-PCs
from 2-12H mice exhibit enhanced Ig secretion in the absence of IL-6, CD40L and TNFα.
The production of Ig occurs in the absence of extrafollicular foci or germinal centers
The differentiation of B cells into antibody secreting cells can occur in extrafollicular areas
or germinal centers (44-48). In addition, prePCs can become activated and secrete antibody
in the absence of forming a defined structure (29). To identify the location of the Ig
secreting, Sm-specific B cells in the 3XKO chimeras, we stained spleen sections four, and
seven days following transfer of 2-12H B cells (IgMa+). As shown in Figure 6A, IgMa+
cells were evident in the spleens of B6 chimeras (left panels) and 3XKO chimeras (right
panel) four days after B cell (2-12H) transfer, but absent in mice not receiving cells. Single
IgMa+ cells were distributed in the follicles (boxed areas 4, and 7 but lacking in box 1) and
extrafollicular space (boxed areas 3, 6, and 9), suggesting a lack of proliferation or the
formation of foci. The transferred cells however, were excluded from the T cell areas.
Similar results were found on day seven (data not shown). Note however, that the infiltration
of DC/MFs into the follicular areas in the 3XKO chimera (compared to B6 chimera) was not
a reproducible finding. To quantitate the numbers of ASCs, we stained serial sections of
spleens with antibodies to IgMa and CD138 then compared the numbers of IgMahi cells that
were CD138+ between B6 and 3XKO chimeras. A representative image of the dual stained
cells that were enumerated from throughout the red pulp and follicles is shown in Figure 6B.
We found that in the 3XKO chimeras, 28% of IgMa+ cells co-stained with CD138. In
comparison, 15% of IgMa+ cells costained with CD138 in the B6 chimera (Figure 6C). This
1.8-fold change (Figure 6C) is similar to the numbers of ASC enumerated by ELISPOT, and
suggests that the IgMa+/CD138+ cells are responsible for Ig secretion. This supports the
data in Figure 5 showing that activation of transferred Sm-specific cells occurs in the
absence of IL-6, CD40L, and TNFα, but not in wildtype mice. Further, the timing of Ig
secretion and the finding that secretion occurs in the absence of organized foci or germinal
centers suggests that the transferred cells rapidly become antibody secreting cells without
Gilbert et al. Page 9













proliferating. This is consistent with previous reports of the activation of the prePCs in
autoimmune mice (29).
Discussion
The genetic and environmental components that underlie SLE are complex, with many
genes likely contributing indirectly to the breakdown of tolerance. Several mechanisms have
been identified that regulate autoreactive B cells activated through the BCR; however, less is
known about how B cells are regulated during TLR activation. Our studies examining the
tolerance mechanisms that regulate TLR4 have shown that the secreted products of activated
DCs and MFs regulate B cells chronically exposed to self-antigen. These products, IL-6 and
sCD40L, repress TLR4-induced Ig by diminishing the number of antibody secreting cells
(22, 23, 36). In this study, we identify TNFα as a third factor secreted by DCs and MFs that
represses autoreactive B cells. We show that loss of DC/MF-mediated tolerance promotes
autoantibody responses from activated pre-plasma cells in mice lacking IL-6, CD40L, and
TNFα. B cell activation occurs in the absence of genetic predisposition, does not involve the
formation of germinal centers or extrafollicular foci, and is not sustained. This suggests that
loss of DC/MF-mediated tolerance could be an early event in the onset of autoimmunity.
The finding that multiple factors secreted by DCs and MFs repress autoreactive B cells
suggests there is a high level of redundancy in maintaining tolerance during TLR4
stimulation. Neutralization studies showed that loss of any single repressive factor did not
restore Ig secretion (Figure 2C and D), or alter the expression levels of the remaining factors
(unpublished observation). However, neutralizing DC or MF conditioned medium with
antibodies to IL-6, TNFα, and CD40L restored Ig secretion (Figure 2C and D), (23) and
DCs and MFs from the 3XKO mice repressed approximately 30% of Ig secretion by
autoreactive B cells (unpublished observations). These data indicate that IL-6 and sCD40L
are the primary soluble factors regulating autoreactive B cells, but that other factors such as
TNFα play a redundant, but less effective, role. The high level of redundancy in the factors
makes it difficult to assess their in vivo role using conditional knockouts. The identity of the
factors conferring additional repressive activity is not under investigation.
The role of TNFα in autoimmunity is seemingly contradictory. Some studies indicate that
TNFα plays an inhibitory role (49-52), while other studies show it promotes the
inflammatory symptoms in murine and human SLE (53-55). These opposing functions of
TNFα are much like those described for the other repressive factors. For example, IL-6
promotes terminal differentiation of naïve B cells but represses autoreactive B cells (22, 56).
However, serum IL-6 levels are elevated in SLE and contribute to the inflammation
associated with disease (57). Similarly, CD40L determines whether activated B cells
differentiate into memory or plasma cells, however soluble CD40L also represses
autoreactive B cells (23, 58, 59). The pleiotropic roles for IL-6, CD40L and TNFα may
indicate that different locations and/or concentrations of the repressive factors determine
tolerance versus inflammation. For example, IL-6 produced by kidney tubular epithelial
cells might contribute to inflammation but the serum levels seen in disease, albeit elevated
compared to healthy controls, are below that required to regulate autoreactive B cells (53,
60).
Our data show that the loss of IL-6, CD40L, and TNFα leads to the activation of
autoreactive B cells. We found that antibody secretion originated from autoreactive prePC
transferred into 3XKO bone marrow chimeras (Figure 5C, 5D), despite the fact that these
mice are not genetically predisposed to autoimmunity. Moreover, the endogenous Ig
responses in 3XKO mice were prolonged compared to those seen in B6 mice (Figure 4A and
4D). This raises the possibility that defects in DC/MF-mediated tolerance lead to early
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autoantibody production perhaps playing a role in initiating the cascade of autoimmune
events leading to disease. Other evidence that supports this idea come from our published
work showing that myeloid cells from lupus-prone mice are defective in secreting IL-6,
sCD40L, and TNFα (23, 36); Figure 3D), and from the work of others showing that gene
ablation of TNFα promotes the onset of lupus-like disease in non-autoimmune-prone NZW
mice (49), treatment of young lupus-prone NZB/W F1 mice with recombinant treatment
(rTNFα) diminishes disease (50), anti-TNFα therapy in rheumatoid arthritis evokes
autoimmunity (52), and human hyper IgM syndrome patients express elevated levels of
antinuclear antibodies and have decreased levels of CD40L consistent with a role in B cell
tolerance (23, 61).
Pre-plasma cells (or plasmablasts) represent an early stage of plasma cell development
characterized by expression of CD138 on B cells that retain expression of B220, CD19 and
surface Ig (B220low CD19+, surface Iglow CD138int/high). These cells are typically short-
lived and in non-autoimmune 2-12H mice, prePCs are enriched in autoreactive specificities
with Sm-specific prePCs represent approximately 15-20% of B6 B cells (29). They fail to
upregulate Blimp-1 and do not spontaneously become ASCs. During TLR4 stimulation,
these cells are regulated by IL-6 and sCD40L (Figure 1B). In autoimmune-prone hosts,
prePCs become activated but do not proliferate or form germinal centers (GCs); rather, they
spontaneously secrete antibody (29). Similarly, in mice lacking IL-6, CD40L, and TNFα,
prePCs become short-lived antibody secreting cells without forming foci in the extracellular
space or entering germinal centers (Figures 5 and 6). The short-lived response likely reflects
the lack of self-renewal in the adoptive transfer model (29) because analysis of endogenous
cells (Figure 4) showed Ig levels remained elevated for 2-3 weeks. It is also possible that the
lack of expansion of the transferred cells might reflect poor survival of the CD138+ Sm B
cells due to the lack of a secondary event conferred by genetic predisposition. Regardless,
the findings confirm the critical role of IL-6, sCD40L, and/or TNFα in regulating pre-PCs,
and indicate that antigen encounter in the absence of tolerance mechanisms can lead to
antibody secretion during TLR4 responses. It remains unclear why transferred FO and MZ B
cells were not activated in the 3XKO mice (Figure 5D) since these subsets are regulated by
IL-6, and/or sCD40L (23). One possibility is that despite in vitro susceptibility to IL-6 and
sCD40L, in vivo FO and MZ cells might be allowed to differentiate to the prePC stage
before reaching another tolerance checkpoint. Alternatively, the transferred MZ and FO cells
might not get adequate signals to further differentiate (62).
The production of autoantibodies to nuclear antigens is strongly dependent on TLR
engagement with the resulting autoantibodies capable of forming immune-complexes that
promote inflammation, glomerular deposition and kidney damage (63-66). Our studies of B
cell tolerance during TLR4 stimulation show that IL-6, sCD40L and TNFα maintain
autoreactive B cells in an unresponsive state by regulating the number of antibody secreting
cells (Figure 3B; 22, 23). This mechanism of tolerance is selective in that IL-6, sCD40L, and
TNFα only repress B cells chronically exposed to self antigen, but not antigenically naïve
cells (Figure 3A, (22, 23). This occurs through receptor crosstalk wherein phospho-ERK is
restricted from the nucleus through a mechanism that integrates the signals produced from
chronic BCR ligation with acute signaling via IL-6 receptor or CD40 leading to the
attenuation of Blimp-1 and XBP-1 expression and TLR4-induced Ig secretion (Lee, Rutan,
and Vilen, manuscript submitted). In vivo, we show that the regulation of autoreactive B
cells also requires DC/MF-mediated tolerance as mice deficient in IL-6, sCD40L and TNFα
show prolonged autoantibody responses, and adoptively transferred autoreactive prePCs
become activated and secrete autoantibody (Figures 4 and 5). It remains unclear whether this
mechanism impacts non-autoreactive B cells chronically encountering foreign antigen on
follicular dendritic cells (FDCs) during GC responses. The requirement for IL-6, CD40L,
and TNFα in maintaining B cell unresponsiveness in the absence of other genetic modifiers
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suggests that this tolerance mechanism might be disrupted in lupus-prone mice. Indeed, we
find that DCs and MFs from lupus-prone mice secrete significantly less IL-6, sCD40L and
TNFα (Figure 3D; 23, 36), and that B cells from lupus-prone mice fail to be repressed by
these soluble factors coincident with the failure to exclude phospho-ERK from the nucleus
upon IL-6 receptor or CD40 engagement (Lee, Rutan, and Vilen, manuscript submitted).
This raises the possibility that defects in DC/MF-mediated tolerance lead to early
autoantibody production perhaps playing a role in initiating the cascade of autoimmune
events leading to disease. The events that underlie the diminished secretion of IL-6, CD40L,
or TNFα by lupus-prone DC/MFs, and those that attenuate the susceptibility of autoreactive
B cells from lupus-prone mice remain unclear, but studies are underway that address the role
of immune complexes in this process.
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Figure 1. TLR4, but not TLR7 or TLR9 stimulated DCs and MFs regulate Sm-specific B cells
(A) Purified 2-12H/Vκ8 (1×105), (B) 2-12H, or (C) B6 B cells were stimulated with Sigma
LPS (30 μg/ml) and cultured with conditioned medium (CM) from LPS-activated BMMF or
BMDC, recombinant IL-6, or sCD40L. (D) 2-12H or B6 B cells stimulated with 1 μg/ml
InvivoGen LPS and cocultured with MF CM prepared from low dose LPS stimulation
(InvivoGen; 10 ng/ml). (E) 2-12H B cells (1×105) stimulated with R848 (1 μg/ml), or (F)
CpG-B (1 μg/ml) cocultured with BMDC or BMMF CM prepared using varying doses of
R848 or CpG-B. Secreted antibody was measured by ELISA from day 4 culture supernatant.
LPS-stimulated purified B cells (100%) secreted an average of 7.7 μg/ml IgMa/κ (2-12H/
Vκ8), 38.5 μg/ml IgMa (2-12H), or 23.3 μg/ml IgM (B6). R848-stimulated cells (100%)
secreted 8.5 μg/ml (2-12H), and CpG-stimulated cells (100%) secreted 5.5 μg/ml (2-12H).
There was no detectable Ig from cells stimulated with the non-CpG ODN. Data represent at
least three independent experiments. Error bars depict SEM. (*** p≤0.001, ** p≤0.01, *
p≤0.05, NS; not significant, p>0.05).
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Figure 2. TNFα represses LPS-induced Ig secretion by Sm-specific B cells
Purified Sm-specific (2-12H/Vκ8) B cells (1×105) were stimulated with LPS (30 μg/ml) and
cultured with (A) conditioned medium (CM) from LPS-activated B6 or IL-6-/- BMDCs and
anti-TNFα antibody (324 μg), or an isotype matched control antibody, (B) recombinant IL-6
(rIL-6; 20 ng/ml), recombinant sCD40L (rsCD40L; 100 ng/ml) or recombinant TNFα
(rTNFα; 50 ng/ml), (C) CM from LPS-activated B6 DCs and anti-IL-6 (50 μg/ml), anti-
TNFα (324 μg), or isotype matched control antibody (D) CM from LPS-activated B6 MF
and anti-IL-6 (50 μg/ml), anti-CD40L (10 μg/ml), anti-TNFα (324 μg), or isotype matched
control antibody. Secreted IgMa/κ was measured by ELISA from day 4 culture supernatant.
LPS-stimulated purified B cells (100%) secreted an average of 3-15 μg/ml IgMa/κ. Data
represent at least three independent experiments. Error bars depict SEM. (* p≤0.05, NS; not
significant, p>0.05).
Gilbert et al. Page 18













Figure 3. TNFα represses autoantibody secretion by reducing the number of ASCs
(A) Purified B cells from the indicated mice were stimulated with LPS (30 μg/ml) and
cultured with rTNFα (50 ng/ml). Total IgM (left) or IgMa/κ (right) was measured by ELISA
from day four culture supernatant. LPS-stimulated B cells (100%) secreted 23-51μg/ml total
IgM or 1-6 μg/ml IgMa/κ. ((B) Sm-specific (2-12H/Vκ8) B cells were stimulated with LPS
(30 μg/ml) in the presence or absence of rTNFα (50 ng/ml) for 3 days. The frequency of
ASCs was determined by ELISPOT. (C) CFSE loaded B cells from 2-12H/Vκ8 mice were
incubated in the presence (black line) or absence (gray shade) of rTNFα (50 ng/ml). The
proliferation indices were 5.6 and 5.5, respectively. The CFSE dilution of LPS stimulated is
shown as a reference (D) BMDCs (left) or BMMF (right) from B6 or MRL/lpr were
stimulated with LPS (30 μg/ml). TNFα was quantitated by ELISA from day four culture
supernatants. Data represent at least three independent experiments. Error bars depict SEM.
(* p≤0.05).
Gilbert et al. Page 19













Figure 4. Innate immune responses induce autoantibodies in mice lacking IL-6, CD40L, and
TNFα (3XKO)
(A) Representative IgM (red) and IgG (green) Hep-2 staining from B6 (top 2 rows) and
3XKO (bottom 2 rows), with (rows 2 and 4) and without (rows 1 and 3) LPS (1.25mg/kg
days 0, 7, and 14). Images were captured at 60X magnification. (B) Compilation of
fluorescence intensity of IgM autoantibodies from LPS-treated B6 (black) and 3XKO
(white) mice. n=10 (C) Compilation of fluorescence intensity of IgG autoantibodies from
LPS-treated B6 (black) and 3XKO (white) mice. n=10 (D) Total anti-nucleosome (IgG,
IgM, IgA) levels from LPS-treated (1.25 mg/kg) B6 (black) and 3XKO (white) mice were
quantitated on the indicated days. n= 7. (E) Total anti-nucleosome (IgG, IgM, IgA) levels
from LPS-treated (0.9 mg/kg) B6 (black) and 3XKO (white) mice were quantitated on the
indicated days. n= 5. Error bars depict SEM. **p≤0.01, * p≤0.05, NS; not significant,
p>0.05).
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Figure 5. Innate immune responses induce the activation of pre-plasma cells in mice lacking
IL-6, CD40L and TNFα (3XKO)
(A) Spleen sections of non-chimeric B6, chimeric B6, non-chimeric 3XKO and chimeric
3XKO stained with B220 (blue), Thy1.2 (green), CD11b and CD11c (both red). Images
were captured at 10X magnification. (B) Chimeric mice (B6 chimeras and 3XKO chimeras)
were injected with LPS (1.25 mg/kg at day -10 and -3). On day 0, 1.5×106 purified Sm-
specific B cells (2-12H/B6) were adoptively transferred. (C) IgMa ASCs were quantitated
by ELISPOT three (left) and twelve (right) days post B cell (2-12H) transfer. (D) Sorted FO,
MZ, and prePC subsets (2-12H) were transferred and IgMa ASCs quantitated by ELISPOT 3
days post transfer. Data are representative of at least three individual experiments totaling
3-6 mice for each experimental condition. Error bars depict SEM. (** p≤0.01, * p≤0.05, NS;
not significant, p>0.05).
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Figure 6. Secretion of Ig by prePCs occurs in the follicles and extrafollicular regions
Chimeric B6 and 3XKO mice were injected with LPS (1.25 mg/kg on day -10 and -3). On
day 0, PBS or 15 × 106 B cells from 2-12H/B6 mice were adoptively transferred. (A) On
day 4, spleens were harvested, sectioned and stained with anti-IgMa (green), anti-B220
(red), and anti-CD11b/CD11c (blue). (Left panels) B6 chimera with and without 2-12H B
cells, (Right panel) 3XKO chimera with 2-12H B cells. White boxes within the image
demark areas of interest that are magnified below each image. In the magnified images,
white carets identify examples of transferred (IgMa +) B cells. (B) Magnified images
depicting IgMa+/CD138+ cells. Left panel: CD138+ (red), middle panel: IgMa+ (green),
and right panel: merged image. (C) Compilation of 128 IgMa+ cells from B6 and 121 from
3XKO mice receiving 2-12H B cells. Three mice were analyzed 4-7 days after transfer of
splenic 2-12H B cells. The percentage of IgMa+ cells that costained with CD138+ cells did
not change between d4 and d7. Error bars depict SEM. (* p≤0.05).
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